Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of TIL plus interleukin-2 versus ipilimumab in metastatic melanoma
NL-OMON53098Phase 3Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of GC101 TIL + pembrolizumab, aldesleukin, ipilimumab, cyclophosphamide and fludarabine in melanoma (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Progression-free survival. Started Sep 2014; status: completed.
02
Drugs
GC101 TIL + pembrolizumabaldesleukinipilimumabcyclophosphamidefludarabine
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON53098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53098.